ACB
Price
$4.91
Change
+$0.08 (+1.66%)
Updated
Sep 5 closing price
Capitalization
276.04M
60 days until earnings call
EVO
Price
$3.48
Change
+$0.11 (+3.26%)
Updated
Sep 5 closing price
Capitalization
1.21B
59 days until earnings call
Interact to see
Advertisement

ACB vs EVO

Header iconACB vs EVO Comparison
Open Charts ACB vs EVOBanner chart's image
Aurora Cannabis
Price$4.91
Change+$0.08 (+1.66%)
Volume$819.6K
Capitalization276.04M
Evotec SE
Price$3.48
Change+$0.11 (+3.26%)
Volume$85.94K
Capitalization1.21B
ACB vs EVO Comparison Chart in %
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. EVO commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and EVO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (ACB: $4.91 vs. EVO: $3.48)
Brand notoriety: ACB: Notable vs. EVO: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 57% vs. EVO: 131%
Market capitalization -- ACB: $276.04M vs. EVO: $1.21B
ACB [@Pharmaceuticals: Generic] is valued at $276.04M. EVO’s [@Pharmaceuticals: Generic] market capitalization is $1.21B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileEVO’s FA Score has 1 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • EVO’s FA Score: 1 green, 4 red.
According to our system of comparison, EVO is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 7 TA indicator(s) are bullish while EVO’s TA Score has 4 bullish TA indicator(s).

  • ACB’s TA Score: 7 bullish, 4 bearish.
  • EVO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ACB is a better buy in the short-term than EVO.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а -9.41% price change this week, while EVO (@Pharmaceuticals: Generic) price change was -0.57% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

ACB is expected to report earnings on Nov 06, 2025.

EVO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EVO($1.21B) has a higher market cap than ACB($276M). ACB YTD gains are higher at: 15.529 vs. EVO (-16.346). ACB has higher annual earnings (EBITDA): 26.6M vs. EVO (-121.33M). EVO has more cash in the bank: 356M vs. ACB (140M). ACB (102M) and EVO (107M) have identical debt. EVO has higher revenues than ACB: EVO (777M) vs ACB (358M).
ACBEVOACB / EVO
Capitalization276M1.21B23%
EBITDA26.6M-121.33M-22%
Gain YTD15.529-16.346-95%
P/E Ratio21.12N/A-
Revenue358M777M46%
Total Cash140M356M39%
Total Debt102M107M95%
FUNDAMENTALS RATINGS
ACB vs EVO: Fundamental Ratings
ACB
EVO
OUTLOOK RATING
1..100
4070
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9395
PRICE GROWTH RATING
1..100
5563
P/E GROWTH RATING
1..100
822
SEASONALITY SCORE
1..100
7575

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACB's Valuation (58) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVO (93) in the null industry. This means that ACB’s stock grew somewhat faster than EVO’s over the last 12 months.

ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as EVO (100) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.

ACB's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as EVO (95) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.

ACB's Price Growth Rating (55) in the Pharmaceuticals Other industry is in the same range as EVO (63) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.

EVO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for ACB (82) in the Pharmaceuticals Other industry. This means that EVO’s stock grew significantly faster than ACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBEVO
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
72%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 5 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
73%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend about 1 month ago
69%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 6 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
85%
Aroon
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIWCX12.300.08
+0.65%
Fidelity SAI International Value Index
FMFCX87.930.53
+0.61%
Fidelity Advisor Materials C
SCHLX40.920.13
+0.32%
DWS Health and Wellness S
VLEQX11.31-0.02
-0.18%
Villere Equity
LAVPX16.17-0.05
-0.31%
Lord Abbett Fundamental Equity P

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been loosely correlated with CGC. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
+1.66%
CGC - ACB
64%
Loosely correlated
+5.80%
OGI - ACB
63%
Loosely correlated
+2.48%
CRON - ACB
54%
Loosely correlated
N/A
TLRY - ACB
53%
Loosely correlated
+3.48%
PAHC - ACB
31%
Poorly correlated
+0.97%
More

EVO and

Correlation & Price change

A.I.dvisor tells us that EVO and ACB have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EVO and ACB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
+3.26%
ACB - EVO
29%
Poorly correlated
+1.66%
OGI - EVO
26%
Poorly correlated
+2.48%
CGC - EVO
23%
Poorly correlated
+5.80%
ELAN - EVO
22%
Poorly correlated
+5.50%
TAK - EVO
22%
Poorly correlated
+0.72%
More